You are browsing the Hong Kong website, Regulated by Hong Kong SFC (CE number: BJA907). Investment is risky and you must be cautious when entering the market.
同方康泰(01312.HK)擬1.6億元出售斯貝福(北京)生物技術55.43%股權
格隆匯 04-06 21:47

格隆匯4月6日丨同方康泰(01312.HK)公吿,於2022年4月6日,公司全資附屬公司同方藥業(作為賣方)、公司控股股東深圳華融泰(作為買方)及目標公司斯貝福(北京)生物技術有限公司訂立股權轉讓協議,據此,同方藥業有條件同意出售而深圳華融泰有條件同意購買銷售股份,相當於目標公司55.43%股權,代價為人民幣1.6億元(須計息)。

於交易完成後,公司將不再持有目標公司的任何權益,而目標集團的財務業績將不再於集團的財務報表內綜合入賬。目標集團包括目標公司及其附屬公司斯貝福(蘇州)。目標公司及斯貝福(蘇州)均為於中國成立的有限責任公司。目標集團主要從事銷售實驗室相關產品。

目標集團主要從事銷售實驗室相關產品。經考慮目標集團的財務表現、審視其業務及經營狀況以及其所屬行業現狀後,公司認為,交易為變現其於目標集團的投資及精簡其業務營運的良機。尤其是,集團目前計劃以更優化的方式配置資源,即集中資源推動集團醫藥業務的增長,更具體而言,推動化學藥、原料藥及中間體以及中藥的製造及銷售等主營業務的增長,而交易正與該計劃相符。集團於交易項下將予收取的代價所得款項淨額預期將用作集團繼續聚焦醫藥業務版塊,包括但不限於投資建設於中國陝西省的新中藥生產基地、同方藥業開展新品研發、拓展新的合作項目,以及集團的一般營運資金。因此,交易將使集團增加其營運資金,加強集團的整體財務狀況,並加速其醫藥業務的發展。

Follow us
Find us on Facebook, Twitter , Instagram, and YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!
Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.
uSMART
Wealth Growth Made Easy
Open Account